市場調査レポート

商品コード

1264002

多発性骨髄腫市場：規模、世界市場の予測（2023年～2030年）、業界動向、成長、シェア、見通し、インフレの影響、企業の機会分析

Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

出版日: 2023年04月01日 | 発行: Renub Research

| ページ情報: 英文 350 Pages | 納期: 即日から翌営業日

価格

Excel (Dashboard)

USD 3,990 626,070円

レポートExcelを１名のみがご利用頂けるライセンスです。Excel内のデータのコピー＆ペーストは可能です。Exceの印刷は一回のみ可能です。

PDF (Single User License)

USD 4,490 704,525円

レポートPDFを1名のみがご利用頂けるライセンスです。PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能です。またPDFの印刷は一人一回可能です。それ以上の印刷をご希望の場合、当社までお問合せください。

PDF (5 User License + Excel)

USD 4,990 782,980円

レポートPDF、Excelを5名のみがご利用頂けるライセンスです。PDF、Excel内のデータのコピー＆ペーストは可能です。PDF、Exceの印刷は一人一回可能です。

PDF (Corporate License)

USD 5,490 861,435円

レポートPDFを会社全体の方がご利用頂けるライセンスです。（子会社、関連会社はご利用できません）PDFファイルは、DRM (デジタル著作権管理システム) 付きです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の多発性骨髄腫の市場規模は、2022年の102億米ドルとなり、2030年には163億1,000万米ドルに達すると予測されています。2022年～2030年にかけて、CAGRで6.04%の成長が見込まれています。

当レポートでは、世界の多発性骨髄腫市場について調査し、疾患の概要とともに、疫学・患者動向、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

疫学シナリオ-主要10ヶ国市場
疫学シナリオ-米国
疫学シナリオ-ドイツ
疫学シナリオ-フランス
疫学シナリオ- 英国
疫学シナリオ-イタリア
疫学シナリオ-スペイン
疫学シナリオ-日本
疫学シナリオ-オーストラリア
疫学シナリオ-中国
疫学シナリオ-サウジアラビア

第12章多発性骨髄腫- 疫学と患者数- 性別

疫学シナリオ-主要10ヶ国市場
疫学シナリオ-米国
疫学シナリオ-ドイツ
疫学シナリオ-フランス
疫学シナリオ-英国
疫学シナリオ-イタリア
疫学シナリオ-スペイン
疫学シナリオ-日本
疫学シナリオ-オーストラリア
疫学シナリオ-中国
疫学シナリオ-サウジアラビア

第13章多発性骨髄腫- 市場シナリオ

市場シナリオ-重要な洞察
市場シナリオ-主要10ヶ国市場
市場シナリオ-米国
市場シナリオ-ドイツ
市場シナリオ-フランス
市場シナリオ-英国
市場シナリオ-イタリア
市場シナリオ-スペイン
市場シナリオ-日本
市場シナリオ-オーストラリア
市場シナリオ-中国
市場シナリオ-サウジアラビア

第14章多発性骨髄腫-治療アルゴリズム、ガイドライン、および医療行為

第15章多発性骨髄腫のアンメットニーズ

第16章多発性骨髄腫-治療の重要なエンドポイント

標的療法
化学療法
その他

第17章多発性骨髄腫-上市済み製品

第18章多発性骨髄腫-開発中の薬剤

第19章企業分析

Sanofi
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Bayer AG
Eli Lilly and Company
Merck &Co., Inc.
AstraZeneca

図表

List of Figures

Figure-01: Global - Multiple Myeloma (MM) Market (Billion US$), 2017 - 2022
Figure-02: Global - Forecast for Multiple Myeloma (MM) Market (Billion US$), 2023 - 2030
Figure-03: Global - Multiple Myeloma (MM) Patient Population (Thousand), 2017 - 2022
Figure-04: Global - Forecast for Multiple Myeloma (MM) Patient Population (THousand), 2023 - 2030
Figure-05: Top 10 Countries - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-06: Top 10 Countries - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-07: United States - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-08: United States - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-09: Germany - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-10: Germany - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-11: France - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-12: France - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-13: United Kingdom - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-14: United Kingdom - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-15: Italy - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-16: Italy - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-17: Spain - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-18: Spain - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-19: Japan - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-20: Japan - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-21: Australia - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-22: Australia - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-23: China - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-24: China - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-25: Saudi Arabia - Epidemiology Scenario Patient Population (Number), 2017 - 2022
Figure-26: Saudi Arabia - Forecast for Epidemiology Scenario Patient Population (Number), 2023 - 2030
Figure-27: Top 10 Countries - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-28: Top 10 Countries - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-29: Top 10 Countries - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-30: Top 10 Countries - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-31: United States - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-32: United States - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-33: United States - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-34: United States - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-35: Germany - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-36: Germany - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-37: Germany - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-38: Germany - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-39: France - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-40: France - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-41: France - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-42: France - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-43: United Kingdom - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-44: United Kingdom - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-45: United Kingdom - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-46: United Kingdom - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-47: Italy - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-48: Italy - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-49: Italy - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-50: Italy - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-51: Spain - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-52: Spain - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-53: Spain - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-54: Spain - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-55: Japan - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-56: Japan - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-57: Japan - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-58: Japan - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-59: Australia - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-60: Australia - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-61: Australia - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-62: Australia - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-63: China - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-64: China - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-65: China - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-66: China - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-67: Saudi Arabia - Epidemiology Scenario Male Patient Population (Number), 2017 - 2022
Figure-68: Saudi Arabia - Forecast for Epidemiology Scenario Male Patient Population (Number), 2023 - 2030
Figure-69: Saudi Arabia - Epidemiology Scenario Female Patient Population (Number), 2017 - 2022
Figure-70: Saudi Arabia - Forecast for Epidemiology Scenario Female Patient Population (Number), 2023 - 2030
Figure-71: Top 10 Countries - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-72: Top 10 Countries - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-73: United States - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-74: United States - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-75: Germany - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-76: Germany - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-77: France - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-78: France - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-79: United Kingdom - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-80: United Kingdom - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-81: Italy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-82: Italy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-83: Spain - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-84: Spain - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-85: Japan - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-86: Japan - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-87: Australia - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-88: Australia - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-89: China - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-90: China - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-91: Saudi Arabia - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-92: Saudi Arabia - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-93: Targeted Therapy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-94: Targeted Therapy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-95: Chemotherapy - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-96: Chemotherapy - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-97: Others - Multiple Myeloma (MM) Market (Million US$), 2017 - 2022
Figure-98: Others - Forecast for Multiple Myeloma (MM) Market (Million US$), 2023 - 2030
Figure-99: Xpovio (Selinexor) - Karyopharm - Market (Million US$), 2018 - 2022
Figure-100: Xpovio (Selinexor) - Karyopharm - Forecast for Market (Million US$), 2023 - 2030
Figure-101: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical - Market (Million US$), 2018 - 2022
Figure-102: Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical - Forecast for Market (Million US$), 2023 - 2030
Figure-103: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) - Market (Million US$), 2018 - 2022
Figure-104: Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan) - Forecast for Market (Million US$), 2023 - 2030
Figure-105: HDAC inhibitor (Farydak) - Novartis - Market (Million US$), 2018 - 2022
Figure-106: HDAC inhibitor (Farydak) - Novartis - Forecast for Market (Million US$), 2023 - 2030
Figure-107: Sarclisa (Isatuximab) - Sanofi - Market (Million US$), 2020 - 2022
Figure-108: Sarclisa (Isatuximab) - Sanofi - Forecast for Market (Million US$), 2023 - 2030
Figure-109: Sanofi - Global Revenue Market (Billion US$), 2018 - 2022
Figure-110: Sanofi - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-111: Pfizer Inc. - Global Revenue Market (Billion US$), 2018 - 2022
Figure-112: Pfizer Inc. - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-113: GlaxoSmithKline plc - Global Revenue Market (Billion US$), 2018 - 2022
Figure-114: GlaxoSmithKline plc - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-115: Novartis AG - Global Revenue Market (Billion US$), 2018 - 2022
Figure-116: Novartis AG - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-117: Bayer AG - Global Revenue Market (Billion US$), 2018 - 2022
Figure-118: Bayer AG - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-119: Eli Lilly and Company - Global Revenue Market (Billion US$), 2018 - 2022
Figure-120: Eli Lilly and Company - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-121: Merck & Co., Inc. - Global Revenue Market (Billion US$), 2018 - 2022
Figure-122: Merck & Co., Inc. - Forecast for Global Revenue Market (Billion US$), 2023 - 2030
Figure-123: AstraZeneca - Global Revenue Market (Billion US$), 2018 - 2022
Figure-124: AstraZeneca - Forecast for Global Revenue Market (Billion US$), 2023 - 2030

List of Tables

Table-01: Global - Multiple Myeloma (MM) Market Share by Countries (Percent), 2018 - 2022
Table-02: Global - Forecast for Multiple Myeloma (MM) Market Share by Countries (Percent), 2023 - 2030
Table-03: Global - Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2018 - 2022
Table-04: Global - Forecast for Multiple Myeloma (MM) Market Share by Treatment Type (Percent), 2023 - 2030
Table-05: Global - Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2018 - 2022
Table-06: Global - Forecast for Multiple Myeloma (MM) Volume Share by Epidemiology Scenario (Percent), 2023 - 2030
Table-07: Global - Multiple Myeloma (MM) Market Share by Gender (Percent), 2018 - 2022
Table-08: Global - Forecast for Multiple Myeloma (MM) Market Share by Gender (Percent), 2023 - 2030

Multiple Myeloma Market will reach US$ 16.31 Billion in 2030 compared to 10.20 Billion in 2022, according to Renub Research. Multiple myeloma, or Kahler's disease, is a cancer that impacts plasma cells, white blood cells that generate antibodies to combat infections. The condition results in an accumulation of abnormal plasma cells in the bone marrow, which produce an abnormal protein called monoclonal immunoglobulin (M protein) that may damage the bones and other organs.

According to the Globocan, there were an estimated 19,292,789 new cancer cases, resulting in approximately 9,958,133 cancer-related deaths. In addition, the International Agency for Research on Cancer (IARC) projects that the global cancer incidence will rise to 27.5 million new cases with 16.3 million deaths by 2040.

Multiple Myeloma testing markets shall experience a CAGR of 6.04% from 2022 to 2030

Multiple myeloma, the second most prevalent type of blood cancer after non-Hodgkin lymphoma, is identified by the uncontrolled growth of abnormal plasma cells within the bone marrow. The malignant plasma cells displace normal blood cells, causing low blood counts, bone deterioration, and possible kidney impairment. Recent advancements in drugs for multiple myeloma have revolutionized treatment in the last decade, and future agents in development offer promising breakthroughs.

An increase in early detection and diagnosis of multiple myeloma leads to earlier treatment and better patient outcomes. Moreover, advancing targeted therapies and immunotherapies have led to the development of newer and more effective treatments for multiple myeloma. Finally, increased awareness and advocacy efforts for multiple myeloma may lead to more research funding and greater attention to the condition, further driving growth in the industry.

Chemotherapy will be the most preferred type of Treatment in the Future

Targeted Therapy, Chemotherapy, and Others are the different treatment types used in the multiple myeloma industry. Chemotherapy is a critical component of multiple myeloma treatment and has contributed to the growth of the chemotherapy market in this field. It effectively kills dividing cancer cells, vital for controlling abnormal plasma cell proliferation. New chemotherapy drugs with improved efficacy and reduced toxicity have increased their use in treating multiple myeloma. Moreover, chemotherapy is often combined with other treatments, such as immunotherapy and targeted therapy, to improve outcomes. Therefore, the demand for chemotherapy treatments will grow as multiple myeloma prevalence increases.

Males are at a greater risk of developing the Disease

Both Male and Female genders are at risk of multiple myeloma. Males have higher levels of androgens that can promote the growth of abnormal plasma cells. Occupational exposure to certain chemicals and risky behaviors such as smoking and heavy alcohol consumption may also increase the risk of multiple myeloma in males. In addition, genetic mutations that increase the risk of multiple myeloma may also be more common in males.

Multiple myeloma is more prevalent in older adults, and since females generally have a longer lifespan than males, they are more susceptible to developing the disease. In addition, some research indicates that female hormones may contribute to developing multiple myeloma. For instance, estrogen may stimulate the proliferation of myeloma cells, elevating the risk of multiple myeloma in females.

United States has the highest Epidemiology Scenario Share

Based on the epidemiology scenario share, the report covers 10 top countries - United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia.The United States' large and diverse population, advanced healthcare system, and robust research infrastructure have contributed to its dominance in the multiple myeloma industry. In addition, the country's favorable regulatory environment for new cancer treatments and numerous patient advocacy organizations have also played a role in the industry's growth.

The UK's robust healthcare system and strong tradition of medical research in multiple myeloma led to a high concentration of healthcare professionals and researchers with expertise in the country, along with a favorable regulatory environment for developing and approving new treatments. Additionally, several organizations' dedication in the UK raises awareness and supports patients and their families, leading to greater attention and funding for research in the field.

China's Increasing Number of Aging Population have increased the incidence of Multiple Myeloma

The United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia are the countries that comprise the multiple myeloma market in this report. China's growing and aging population has led to a higher incidence of multiple myeloma and growth in the industry. Increased healthcare spending due to economic development has improved cancer care, including for multiple myeloma. China's diverse patient population presents opportunities for new treatments and clinical trials, while government policies support the biopharmaceutical industry. Renowned research institutions and collaborations with international pharmaceutical companies have contributed to the transfer of advanced technologies and growth in the industry.

Renub Research report titled "Multiple Myeloma Market Global Forecast by Countries (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia), Treatment Types (Targeted therapy, Chemotherapy, and Others), Epidemiology Scenario Share (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia), Gender share (Male, and Female)," provides a detailed analysis of Multiple Myeloma Market.

Countries - Market breakup from 10 Viewpoints:

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Saudi Arabia

Treatment Types - Market breakup from 3 Viewpoints:

1. Targeted therapy

2. Chemotherapy

3. Others

Epidemiology Scenario Share - Market breakup from 10 Viewpoints:

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Australia

Gender Share - Market breakup from 2 Viewpoints:

1. Male

2. Female

All companies have been covered from 3 viewpoints

Overviews
Recent Developments
Revenues

Company

1. Sanofi (France)

2. Pfizer Inc. (US)

3. GlaxoSmithKline plc (UK)

4. Novartis AG (Switzerland)

5. Bayer AG (Germany)

6. Eli Lilly and Company (US)

7. Merck & Co., Inc. (US)

8. AstraZeneca

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities

5. Porter's Five Forces

5.1 Bargaining Power of Buyers
5.2 Bargaining Power of Suppliers
5.3 Degree of Competition
5.4 Threat of New Entrants
5.5 Threat of Substitutes

6 SWOT Analysis - Multiple Myeloma Market

6.1 Strengths
6.2 Weaknesses
6.3 Opportunities
6.4 Threats

7. Global Multiple Myeloma (MM) - Market & Patient Numbers

7.1 Multiple Myeloma Market
7.2 Multiple Myeloma Patient Population

8. Share Analysis - Global Multiple Myeloma

8.1 By Countries Market Share
8.2 By Treatment Types Market Share
8.3 By Epidemiology Scenario Share
8.4 By Gender Share

9. Multiple Myeloma - Disease Overview

9.1 Introduction
9.2 Symptoms and Diagnosis
9.3 Pathophysiology
9.4 Causes and Risk Factors
9.5 Treatment

10. Multiple Myeloma Patient Journey

11. Multiple Myeloma - Epidemiology and Patient Population

11.1 Epidemiology Scenario - Top 10 Markets
- 11.1.1 Epidemiology Scenario (2017-2022)
- 11.1.2 Epidemiology Forecast (2023-2030)
11.2 Epidemiology Scenario - United States
- 11.2.1 Epidemiology Scenario (2017-2022)
- 11.2.2 Epidemiology Forecast (2023-2030)
11.3 Epidemiology Scenario - Germany
- 11.3.1 Epidemiology Scenario (2017-2022)
- 11.3.2 Epidemiology Forecast (2023-2030)
11.4 Epidemiology Scenario - France
- 11.4.1 Epidemiology Scenario (2017-2022)
- 11.4.2 Epidemiology Forecast (2023-2030)
11.5 Epidemiology Scenario - United Kingdom
- 11.5.1 Epidemiology Scenario (2017-2022)
- 11.5.2 Epidemiology Forecast (2023-2030)
11.6 Epidemiology Scenario - Italy
- 11.6.1 Epidemiology Scenario (2017-2022)
- 11.6.2 Epidemiology Forecast (2023-2030)
11.7 Epidemiology Scenario - Spain
- 11.7.1 Epidemiology Scenario (2017-2022)
- 11.7.2 Epidemiology Forecast (2023-2030)
11.8 Epidemiology Scenario - Japan
- 11.8.1 Epidemiology Scenario (2017-2022)
- 11.8.2 Epidemiology Forecast (2023-2030)
11.9 Epidemiology Scenario - Australia
- 11.11.1 Epidemiology Scenario (2017-2022)
- 11.11.2 Epidemiology Forecast (2023-2030)
11.10 Epidemiology Scenario - China
- 11.10.1 Epidemiology Scenario (2017-2022)
- 11.10.2 Epidemiology Forecast (2023-2030)
11.11 Epidemiology Scenario - Saudi Arabia
- 11.11.1 Epidemiology Scenario (2017-2022)
- 11.11.2 Epidemiology Forecast (2023-2030)

12. Multiple Myeloma - Epidemiology and Patient Population - By Gender

12.1 Epidemiology Scenario - Top 10 Markets
- 12.1.1 Epidemiology Scenario Male and Forecast
- 12.1.2 Epidemiology Scenario Female Forecast
12.2 Epidemiology Scenario - United States
- 12.2.1 Epidemiology Scenario Male and Forecast
- 12.2.2 Epidemiology Scenario Female Forecast
12.3 Epidemiology Scenario - Germany
- 12.3.1 Epidemiology Scenario Male and Forecast
- 12.3.2 Epidemiology Scenario Female Forecast
12.4 Epidemiology Scenario - France
- 12.4.1 Epidemiology Scenario Male and Forecast
- 12.4.2 Epidemiology Scenario Female Forecast
12.5 Epidemiology Scenario - United Kingdom
- 12.5.1 Epidemiology Scenario Male and Forecast
- 12.5.2 Epidemiology Scenario Female Forecast
12.6 Epidemiology Scenario - Italy
- 12.6.1 Epidemiology Scenario Male and Forecast
- 12.6.2 Epidemiology Scenario Female Forecast
12.7 Epidemiology Scenario - Spain
- 12.7.1 Epidemiology Scenario Male and Forecast
- 12.7.2 Epidemiology Scenario Female Forecast
12.8 Epidemiology Scenario - Japan
- 12.8.1 Epidemiology Scenario Male and Forecast
- 12.8.2 Epidemiology Scenario Female Forecast
12.9 Epidemiology Scenario - Australia
- 12.9.1 Epidemiology Scenario Male and Forecast
- 12.9.2 Epidemiology Scenario Female Forecast
12.10 Epidemiology Scenario - China
- 12.12.1 Epidemiology Scenario Male and Forecast
- 12.12.2 Epidemiology Scenario Female Forecast
12.11 Epidemiology Scenario - Saudi Arabia
- 12.11.1 Epidemiology Scenario Male and Forecast
- 12.11.2 Epidemiology Scenario Female Forecast

13. Multiple Myeloma - Market Scenario

13.1 Market Scenario - Key Insights
13.2 Market Scenario - Top 10 Markets
- 13.2.1 Multiple Myeloma - Market Size (2017-2022)
- 13.2.2 Market Forecast (2023-2030)
13.3 Market Scenario - United States
- 13.3.1 Multiple Myeloma - Market Size (2017-2022)
- 13.3.2 Market Size Forecast (2023-2030)
- 13.3.3 Multiple Myeloma - Access and Reimbursement Overview
13.4 Market Scenario - Germany
- 13.4.1 Multiple Myeloma - Market Size (2017-2022)
- 13.4.2 Market Size Forecast (2023-2030)
- 13.4.3 Multiple Myeloma - Access and Reimbursement Overview
13.5 Market Scenario - France
- 13.5.1 Multiple Myeloma - Market Size (2017-2022)
- 13.5.2 Market Size Forecast (2023-2030)
- 13.5.3 Multiple Myeloma - Access and Reimbursement Overview
13.6 Market Scenario - United Kingdom
- 13.6.1 Multiple Myeloma - Market Size (2017-2022)
- 13.6.2 Market Size Forecast (2023-2030)
- 13.6.3 Multiple Myeloma - Access and Reimbursement Overview
13.7 Market Scenario - Italy
- 13.7.1 Multiple Myeloma - Market Size (2017-2022)
- 13.7.2 Market Size Forecast (2023-2030)
- 13.7.3 Multiple Myeloma - Access and Reimbursement Overview
13.8 Market Scenario - Spain
- 13.8.1 Multiple Myeloma - Market Size (2017-2022)
- 13.8.2 Market Size Forecast (2023-2030)
- 13.8.3 Multiple Myeloma - Access and Reimbursement Overview
13.9 Market Scenario - Japan
- 13.9.1 Multiple Myeloma - Market Size (2017-2022)
- 13.9.2 Market Size Forecast (2023-2030)
- 13.9.3 Multiple Myeloma - Access and Reimbursement Overview
13.10 Market Scenario - Australia
- 13.10.1 Multiple Myeloma - Market Size (2017-2022)
- 13.10.2 Market Size Forecast (2023-2030)
- 13.10.3 Multiple Myeloma - Access and Reimbursement Overview
13.11 Market Scenario - China
- 13.13.1 Multiple Myeloma - Market Size (2017-2022)
- 13.13.2 Market Size Forecast (2023-2030)
- 13.13.3 Multiple Myeloma - Access and Reimbursement Overview
13.12 Market Scenario - Saudi Arabia
- 13.12.1 Multiple Myeloma - Market Size (2017-2022)
- 13.12.2 Market Size Forecast (2023-2030)
- 13.12.3 Multiple Myeloma - Access and Reimbursement Overview

14. Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices

14.1 Guidelines, Management and Treatment
14.2 Treatment Algorithm

15. Multiple Myeloma Unmet Needs

16. Multiple Myeloma - Key Endpoints of Treatment

16.1 Targeted Therapy
16.2 Chemotherapy
16.3 Others

17. Multiple Myeloma - Marketed Products

17.1 List of Multiple Myeloma Marketed Drugs across the Top 10 Markets
- 17.1.1 Xpovio (Selinexor) - Karyopharm
  - 17.1.1.1 Drug Overview
  - 17.1.1.2 Mechanism of Action
  - 17.1.1.3 Regulatory Status
  - 17.1.1.4 Clinical Trial Results
  - 17.1.1.5 Sales Across Major Markets
- 17.1.2 Velcade (Bortezomib) - Takeda Pharmaceutical/Janssen Pharmaceutical
  - 17.1.2.1 Drug Overview
  - 17.1.2.2 Mechanism of Action
  - 17.1.2.3 Regulatory Status
  - 17.1.2.4 Clinical Trial Results
  - 17.1.2.5 Sales Across Major Markets
- 17.1.3 Proteasome inhibitor (Kyprolis)- Amgen / Ono (Japan)
  - 17.1.3.1 Drug Overview
  - 17.1.3.2 Mechanism of Action
  - 17.1.3.3 Regulatory Status
  - 17.1.3.4 Clinical Trial Results
  - 17.1.3.5 Sales Across Major Markets
- 17.1.4 HDAC inhibitor (Farydak) - Novartis
  - 17.1.4.1 Drug Overview
  - 17.1.4.2 Mechanism of Action
  - 17.1.4.3 Regulatory Status
  - 17.1.4.4 Clinical Trial Results
  - 17.1.4.5 Sales Across Major Markets
- 17.1.5 Sarclisa (Isatuximab) - Sanofi
  - 17.1.5.1 Drug Overview
  - 17.1.5.2 Mechanism of Action
  - 17.1.5.3 Regulatory Status
  - 17.1.5.4 Clinical Trial Results
  - 17.1.5.5 Sales Across Major Markets

18. Multiple Myeloma - Pipeline Drugs

18.1 List of Multiple Myeloma Pipeline Drugs across the Top 10 Markets
- 18.1.1 Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
  - 18.1.1.1 Drug Overview
  - 18.1.1.2 Mechanism of Action
  - 18.1.1.3 Clinical Trial Results
  - 18.1.1.4 Safety and Efficacy
  - 18.1.1.5 Regulatory Status
- 18.1.2 Elranatamab - Pfizer
  - 18.1.2.1 Drug Overview
  - 18.1.2.2 Mechanism of Action
  - 18.1.2.3 Clinical Trial Results
  - 18.1.2.4 Safety and Efficacy
  - 18.1.2.5 Regulatory Status
- 18.1.3 Alnuctamab - Celgene, Bristol-Myers Squibb
  - 18.1.3.1 Drug Overview
  - 18.1.3.2 Mechanism of Action
  - 18.1.3.3 Clinical Trial Results
  - 18.1.3.4 Safety and Efficacy
  - 18.1.3.5 Regulatory Status
- 18.1.4 CAR-T ddBCMA - Gilead Sciences
  - 18.1.4.1 Drug Overview
  - 18.1.4.2 Mechanism of Action
  - 18.1.4.3 Clinical Trial Results
  - 18.1.4.4 Safety and Efficacy
  - 18.1.4.5 Regulatory Status
- 18.1.5 Masitinib - AB Science
  - 18.1.5.1 Drug Overview
  - 18.1.5.2 Mechanism of Action
  - 18.1.5.3 Clinical Trial Results
  - 18.1.5.4 Safety and Efficacy
  - 18.1.5.5 Regulatory Status
- 18.1.6 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
  - 18.1.6.1 Drug Overview
  - 18.1.6.2 Mechanism of Action
  - 18.1.6.3 Clinical Trial Results
  - 18.1.6.4 Safety and Efficacy
  - 18.1.6.5 Regulatory Status

19. Company Analysis

19.1 Sanofi (France)
- 19.1.1 Overview
- 19.1.2 Recent Developments
- 19.1.3 Financial Analysis
19.2 Pfizer Inc. (US)
- 19.2.1 Overview
- 19.2.2 Recent Developments
- 19.2.3 Financial Analysis
19.3 GlaxoSmithKline plc (UK)
- 19.3.1 Overview
- 19.3.2 Recent Developments
- 19.3.3 Financial Analysis
19.4 Novartis AG (Switzerland)
- 19.4.1 Overview
- 19.4.2 Recent Developments
- 19.4.3 Financial Analysis
19.5 Bayer AG (Germany)
- 19.5.1 Overview
- 19.5.2 Recent Developments
- 19.5.3 Financial Analysis
19.6 Eli Lilly and Company (US)
- 19.6.1 Overview
- 19.6.2 Recent Developments
- 19.6.3 Financial Analysis
19.7 Merck & Co., Inc. (US)
- 19.7.1 Overview
- 19.7.2 Recent Developments
- 19.7.3 Financial Analysis
19.8 AstraZeneca
- 19.8.1 Overview
- 19.8.2 Recent Developments
- 19.8.3 Financial Analysis

多発性骨髄腫市場：規模、世界市場の予測（2023年～2030年）、業界動向、成長、シェア、見通し、インフレの影響、企業の機会分析

Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

第5章 ポーターのファイブフォース

第6章 SWOT分析- 多発性骨髄腫市場

第7章 世界の多発性骨髄腫（MM）- 市場と患者数

第8章 シェア分析- 世界の多発性骨髄腫

第9章 多発性骨髄腫- 疾患の概要

第10章 多発性骨髄腫の患者動向

第11章 多発性骨髄腫- 疫学と患者数

第12章 多発性骨髄腫- 疫学と患者数- 性別

第13章 多発性骨髄腫- 市場シナリオ

第14章 多発性骨髄腫-治療アルゴリズム、ガイドライン、および医療行為

第15章 多発性骨髄腫のアンメットニーズ

第16章 多発性骨髄腫-治療の重要なエンドポイント

第17章 多発性骨髄腫-上市済み製品

第18章 多発性骨髄腫-開発中の薬剤

第19章 企業分析

List of Figures

List of Tables

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Saudi Arabia

1. Targeted therapy

2. Chemotherapy

3. Others

1. United States

2. United Kingdom

3. Germany

4. France

5. Spain

6. Italy

7. Japan

8. Australia

9. China

10. Australia

1. Male

2. Female

1. Sanofi (France)

2. Pfizer Inc. (US)

3. GlaxoSmithKline plc (UK)

4. Novartis AG (Switzerland)

5. Bayer AG (Germany)

6. Eli Lilly and Company (US)

7. Merck & Co., Inc. (US)

8. AstraZeneca

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

5. Porter's Five Forces

7. Global Multiple Myeloma (MM) - Market & Patient Numbers

8. Share Analysis - Global Multiple Myeloma

9. Multiple Myeloma - Disease Overview

10. Multiple Myeloma Patient Journey

11. Multiple Myeloma - Epidemiology and Patient Population

12. Multiple Myeloma - Epidemiology and Patient Population - By Gender

13. Multiple Myeloma - Market Scenario

14. Multiple Myeloma - Treatment Algorithm, Guidelines, and Medical Practices

15. Multiple Myeloma Unmet Needs

16. Multiple Myeloma - Key Endpoints of Treatment

17. Multiple Myeloma - Marketed Products

18. Multiple Myeloma - Pipeline Drugs

19. Company Analysis

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章市場力学

第5章ポーターのファイブフォース

第7章世界の多発性骨髄腫（MM）- 市場と患者数

第8章シェア分析- 世界の多発性骨髄腫

第9章多発性骨髄腫- 疾患の概要

第10章多発性骨髄腫の患者動向

第11章多発性骨髄腫- 疫学と患者数

第12章多発性骨髄腫- 疫学と患者数- 性別

第13章多発性骨髄腫- 市場シナリオ

第14章多発性骨髄腫-治療アルゴリズム、ガイドライン、および医療行為

第15章多発性骨髄腫のアンメットニーズ

第16章多発性骨髄腫-治療の重要なエンドポイント

第17章多発性骨髄腫-上市済み製品

第18章多発性骨髄腫-開発中の薬剤

第19章企業分析